These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 15863798

  • 1. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [Abstract] [Full Text] [Related]

  • 2. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T, Uzcátegui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, de Baptista EA.
    Psychiatry Res; 2008 May 30; 159(1-2):250-3. PubMed ID: 18374423
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
    Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC.
    Acta Psychiatr Scand; 2007 Feb 30; 115(2):101-5. PubMed ID: 17244173
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 30; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 5. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 30; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.
    Am J Psychiatry; 2008 Mar 30; 165(3):352-8. PubMed ID: 18245179
    [Abstract] [Full Text] [Related]

  • 7. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
    Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.
    Clin Schizophr Relat Psychoses; 2011 Apr 30; 5(1):17-25. PubMed ID: 21459735
    [Abstract] [Full Text] [Related]

  • 8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 30; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan 30; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 10. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL.
    JAMA; 2003 Apr 09; 289(14):1805-12. PubMed ID: 12684359
    [Abstract] [Full Text] [Related]

  • 11. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE.
    Bipolar Disord; 2007 Jun 09; 9(4):426-34. PubMed ID: 17547588
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study.
    Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, Walsh BT, Sibutramine Binge Eating Disorder Research Group.
    Am J Psychiatry; 2008 Jan 09; 165(1):51-8. PubMed ID: 18056225
    [Abstract] [Full Text] [Related]

  • 13. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2001 May 09; 25(5):741-7. PubMed ID: 11360159
    [Abstract] [Full Text] [Related]

  • 14. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.
    J Clin Psychiatry; 2004 May 09; 65 Suppl 18():47-56. PubMed ID: 15600384
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.
    J Clin Psychiatry; 2008 Jul 09; 69(7):1046-56. PubMed ID: 18605811
    [Abstract] [Full Text] [Related]

  • 16. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A.
    Clin Ther; 2005 Dec 09; 27(12):1930-41. PubMed ID: 16507379
    [Abstract] [Full Text] [Related]

  • 17. Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.
    Biedermann F, Fleischhacker WW, Kemmler G, Ebenbichler CF, Lechleitner M, Hofer A.
    Int Clin Psychopharmacol; 2014 May 09; 29(3):181-4. PubMed ID: 24300751
    [Abstract] [Full Text] [Related]

  • 18. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A, Krause J.
    JAMA; 2001 Sep 19; 286(11):1331-9. PubMed ID: 11560538
    [Abstract] [Full Text] [Related]

  • 19. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan 19; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

  • 20. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
    Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO.
    Am J Psychiatry; 2005 Sep 19; 162(9):1744-6. PubMed ID: 16135638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.